Abstract
A study was made of the efficacy and safety of Sisomicin (Extramycin: Bayer) nebulizer in 31 patients with sinusitis treated with 25mg twice a week for 4 weeks or longer and 16 patients with laryngitis were treated with the same dose twice a week for 2 weeks or longer.
1. The Sisomicin concentration in the blood was 0.08μg/ml or less in all cases after the nebulizer treatment.
Accumulation of Sisomicin in the blood was not observed.
2. Subjective symptoms were relieved in 74.2% of the patients with sinusitis, objective signs were relieved in 67.7%, bacteria were eradicated in 52%, and the rate of usefulness was 74.2%.
3. Subjective symptoms and objective signs were relieved in 100% of the patients with laryngitis, bacteria were eradicated in 77.8%, and the rate of usefulness was 100%.
4. No side effects were observed in any of the patients in these experiments.
